BiotechTube

Venetoclax Combining Chidamide and Azacitidine (VCA) regimen followed by dicitabine combined with liposome mitoxantrone, cytarabine, and G-CSF (D-MAG) regimen

Phase 2Recruiting
0 watching 0 views this week⚡ Active
51
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Leukemia, Myeloid, Acute

Conditions

Leukemia, Myeloid, Acute, AML Stage, Adult

Trial Timeline

Dec 1, 2022 → Dec 31, 2026

NCT ID
NCT05603884

About Venetoclax Combining Chidamide and Azacitidine (VCA) regimen followed by dicitabine combined with liposome mitoxantrone, cytarabine, and G-CSF (D-MAG) regimen

Venetoclax Combining Chidamide and Azacitidine (VCA) regimen followed by dicitabine combined with liposome mitoxantrone, cytarabine, and G-CSF (D-MAG) regimen is a phase 2 stage product being developed by CSPC Pharmaceutical Group Limited for Leukemia, Myeloid, Acute. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05603884. Target conditions include Leukemia, Myeloid, Acute, AML Stage, Adult.

Hype Score Breakdown

Clinical
17
Activity
12
Company
9
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT05603884Phase 2Recruiting

Competing Products

20 competing products in Leukemia, Myeloid, Acute

See all competitors
ProductCompanyStageHype Score
AFM28AffimedPhase 1
25
Mitoxantrone hydrochloride liposome Injection-based bridging therapy+ Fludarabine-based chemotherapy +CD19 CAR-T CellsCSPC Pharmaceutical Group LimitedPhase 2
51
TERN-701Terns PharmaceuticalsPhase 1/2
38
Fludarabine + Cyclophosphamide + PRGN-3007PrecigenPhase 1
28
PRGN-3006 T CellsPrecigenPhase 1
28
BisantreneRace OncologyPhase 2
44
Bisantrene Dihydrochloride (high dose) + Bisantrene Dihydrochloride (low dose) + Cytarabine Hydrochloride + Decitabine and cedazuridineRace OncologyPhase 1
25
Bisantrene + Fludarabine + ClofarabineRace OncologyPhase 2
44
ZN-d5 ZN-c3 + ZN-c3Zentalis PharmaceuticalsPhase 1/2
33
ZN-d5Zentalis PharmaceuticalsPhase 1
25
Pirtobrutinib + Venetoclax + RituximabEli LillyPhase 3
77
PirtobrutinibEli LillyPhase 2
52
Ibrutinib + LY3214996Eli LillyPhase 1
33
Pirtobrutinib + AcalabrutinibEli LillyPhase 2
52
VIP943 (QW) + VIP943 (BIW)Vincerx PharmaPhase 1
25
Pirtobrutinib + IbrutinibEli LillyPhase 3
77
LY2523355Eli LillyPhase 1
33
TomivosertibeFFECTOR TherapeuticsPhase 1
25
gemtuzumab ozogamycinChugai PharmaceuticalPhase 3
77
Quizartinib High Dose + Quizartinib Low DoseDaiichi SankyoPhase 2
52

Other Products from CSPC Pharmaceutical Group Limited

Butylphthalide + Butylphthalide placeboPhase 3
76
Mitoxantrone hydrochloride liposome Injection-based bridging therapy+ Fludarabine-based chemotherapy +CD19 CAR-T CellsPhase 2
51
Sintilimab + Nab paclitaxel + CisplatinPhase 2
51
pegylated liposomal doxorubicin (PLD) + PD-1Phase 2
51
liposomal irinotecan monotherapy + liposomal irinotecan monotherapy + Liposomal Irinotecan + rmhTNF-NC + Liposomal Irinotecan + BevacizumabPhase 1/2
40